Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE ABOUT TOGETHER… the Regulus team is focused on the discovery and development of microRNA therapeutics. Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals, now Ionis Pharmaceuticals (NASDAQ:IONS), and has continued to build upon its thought leadership, knowledge base and intellectual property. About microRNA Dysregulated microRNA expression is a key factor in many complex multi-factorial diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. microRNA therapeutics are oligonucleotides that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat a broad range of human disease. microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes, each of which is involved in biological networks or pathways. TOGETHER WE… © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact

Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE IN THE COMMUNITY At Regulus, we are compelled to give back and make meaningful contributions to society. We believe that philanthropy fuels change, mentoring makes a difference and many sets of hands are better than one. Through continuous and incremental acts of kindness we can achieve greater outcomes for our communities and our patients. Our employees are currently involved in a variety of different charitable events, some of which include: PKD Foundation The Alport Syndrome Foundation San Diego Food Bank San Diego Walk for PKD © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact